Bashashati Mohammad, Habibi Hamid R, Keshavarzian Ali, Schmulson Max, Sharkey Keith A
Department of Internal Medicine, Texas Tech University, Health Sciences Center, Paul L. Foster School of Medicine, 4800 Alberta Ave, El Paso, TX 79905, USA.
Curr Drug Targets. 2015;16(3):199-208. doi: 10.2174/1389450116666150120104012.
Inflammatory bowel diseases (IBD) are chronic, relapsing and remitting gastrointestinal (GI) disorders of unknown etiology. IBD patients commonly exhibit extra-intestinal manifestations and complications of an inflammatory nature, presenting with disorders such as ankylosing spondylitis, uveitis and vasculitis. Although the metabolic syndrome is less prevalent in patients with IBD, they are at an increased risk for atherosclerosis and cardiovascular events. Considerable evidence supports the role of GI microbiota in the development of IBD. Recent studies have also shown a significant interaction between the metabolites of gut microbiota and the development of cardiovascular disease. Here we hypothesize that dysbiosis and/or abnormalities in the function of the intestinal microbiota promote cardiovascular disease in IBD patients, explaining the increased risk of cardiovascular events in these patients.
炎症性肠病（IBD）是病因不明的慢性、复发性和缓解性胃肠道疾病。IBD患者通常表现出肠道外的炎症性表现和并发症，如强直性脊柱炎、葡萄膜炎和血管炎等疾病。尽管代谢综合征在IBD患者中不太常见，但他们患动脉粥样硬化和心血管事件的风险增加。大量证据支持肠道微生物群在IBD发病中的作用。最近的研究还表明，肠道微生物群的代谢产物与心血管疾病的发生之间存在显著相互作用。在此，我们假设肠道微生物群的失调和/或功能异常会促进IBD患者发生心血管疾病，这解释了这些患者心血管事件风险增加的原因。
